Valuation: Summit Corporation plc

Market Cap 1.02TCr 1.35TCr 1.19TCr 1.13TCr 1.92TCr 1,29300Cr 1.94TCr 13TCr 5.18TCr 66TCr 5.07TCr 4.95TCr 2,12000Cr P/E 2026 *
-14.7x
P/E 2027 * -14.5x
Enterprise Value 969.11Cr 1.29TCr 1.13TCr 1.07TCr 1.83TCr 1,23400Cr 1.85TCr 13TCr 4.94TCr 63TCr 4.83TCr 4.73TCr 2,02200Cr EV / Sales 2026 *
3,305x
EV / Sales 2027 * 238x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
22/09 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
15/09 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
15/09 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
10/09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09/09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
26/08 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
26/08 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
26/08 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
26/08 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
25/08 Wall Street Wants Receipts Zonebourse
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.40%+1.03%+27.52%+80.60% 6.01TCr
-1.15%-0.21%+6.40%+35.27% 4.82TCr
-0.05%+0.37%+41.54%+36.65% 4.43TCr
+0.38%+7.61%+339.53%+641.55% 4.4TCr
+0.18%+0.26%+7.41%+103.45% 4.16TCr
-0.67%+0.17%+7.60%+46.37% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-1.29%-3.55%-20.74%+352.04% 2.49TCr
Average +0.74%+1.53%+55.04%+156.99% 4.41TCr
Weighted average by Cap. +0.94%+1.53%+59.25%+147.53%

Financials

2026 *2027 *
Net sales 29.32L 38.93L 34.28L 32.48L 55.26L 37Cr 55.98L 3.89Cr 1.5Cr 19Cr 1.46Cr 1.43Cr 61Cr 4.19Cr 5.56Cr 4.89Cr 4.64Cr 7.89Cr 532.86Cr 7.99Cr 55Cr 21Cr 272.41Cr 21Cr 20Cr 873.35Cr
Net income -70Cr -93Cr -82Cr -77Cr -131.56Cr -8.89TCr -133.26Cr -925.1Cr -356.01Cr -4.54TCr -347.99Cr -340.4Cr -15TCr -74Cr -98Cr -87Cr -82Cr -139.53Cr -9.42TCr -141.33Cr -981.11Cr -377.56Cr -4.82TCr -369.06Cr -361.01Cr -15TCr
Net Debt -47Cr -62Cr -55Cr -52Cr -89Cr -5.98TCr -90Cr -622.78Cr -239.66Cr -3.06TCr -234.27Cr -229.16Cr -9.8TCr -20Cr -27Cr -23Cr -22Cr -38Cr -2.55TCr -38Cr -265.22Cr -102.06Cr -1.3TCr -100Cr -98Cr -4.18TCr
Logo Summit Corporation plc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-